Insider Selling: Cerus Co. (CERS) CFO Sells $15,556.97 in Stock

Cerus Co. (NASDAQ:CERS) CFO Kevin Dennis Green sold 2,783 shares of the company’s stock in a transaction that occurred on Thursday, January 10th. The shares were sold at an average price of $5.59, for a total value of $15,556.97. Following the sale, the chief financial officer now owns 63,608 shares in the company, valued at $355,568.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Kevin Dennis Green also recently made the following trade(s):

  • On Monday, December 10th, Kevin Dennis Green sold 2,783 shares of Cerus stock. The shares were sold at an average price of $5.35, for a total value of $14,889.05.
  • On Monday, November 12th, Kevin Dennis Green sold 2,783 shares of Cerus stock. The shares were sold at an average price of $5.56, for a total value of $15,473.48.

Shares of NASDAQ CERS opened at $5.61 on Monday. The company has a current ratio of 3.48, a quick ratio of 3.17 and a debt-to-equity ratio of 0.26. The firm has a market cap of $774.78 million, a price-to-earnings ratio of -10.02 and a beta of 1.33. Cerus Co. has a 12-month low of $3.77 and a 12-month high of $8.05.

Cerus (NASDAQ:CERS) last announced its earnings results on Thursday, November 1st. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). The business had revenue of $15.40 million for the quarter, compared to analysts’ expectations of $15.40 million. Cerus had a negative return on equity of 68.90% and a negative net margin of 74.95%. The business’s revenue for the quarter was up 42.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.12) EPS. As a group, equities research analysts expect that Cerus Co. will post -0.43 EPS for the current year.

CERS has been the topic of several recent analyst reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $9.00 price target on shares of Cerus in a report on Monday, December 10th. ValuEngine downgraded Cerus from a “strong-buy” rating to a “buy” rating in a report on Monday, November 12th. Zacks Investment Research upgraded Cerus from a “hold” rating to a “buy” rating and set a $8.00 price objective on the stock in a report on Wednesday, October 3rd. Finally, BidaskClub upgraded Cerus from a “sell” rating to a “hold” rating in a report on Saturday, December 15th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. Cerus has a consensus rating of “Hold” and a consensus target price of $9.00.

Hedge funds and other institutional investors have recently made changes to their positions in the business. First Quadrant L P CA bought a new stake in Cerus during the 3rd quarter valued at $112,000. Mackenzie Financial Corp bought a new stake in Cerus during the 3rd quarter valued at $119,000. Paloma Partners Management Co bought a new stake in Cerus during the 2nd quarter valued at $150,000. Prudential Financial Inc. boosted its position in Cerus by 110.2% during the 3rd quarter. Prudential Financial Inc. now owns 25,403 shares of the biotechnology company’s stock valued at $183,000 after acquiring an additional 13,320 shares in the last quarter. Finally, Capital Fund Management S.A. bought a new stake in Cerus during the 3rd quarter valued at $217,000. 60.58% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Cerus Co. (CERS) CFO Sells $15,556.97 in Stock” was published by Markets Daily and is owned by of Markets Daily. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.themarketsdaily.com/2019/01/14/insider-selling-cerus-co-cers-cfo-sells-15556-97-in-stock.html.

About Cerus

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.

Read More: Understanding Relative Strength Index

Insider Buying and Selling by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply